Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 878-888

  Beyer, J ^a   Albers, P ^b   Altena, R ^c   Aparicio, J ^d   Bokemeyer, C ^e   Busch, J ^f   Cathomas, R ^g   Cavallin Stahl, E ^h   Clarke, N W ⁱ   Classen J ^j   Cohn Cedermark, G ^k   Dahl, A A ^l   Daugaard, G ^m   De Giorgi, U ⁿ   De Santis, M ^o   De Wit, M ^p   Dewit, R ^q   Dieckmann, K P ^r   Fenner, M ^s   Fizazi, K ^t   Flechon, A ^u   Fossa, S D ^l   Germa Lluch J R ^v   Gietema, J A ^c   Gillessen, S ^w   Giwercman, A ^h   Hartmann, J T ^x   Heidenreich, A ^y   Hentrich, M ^z   Honecker, F ^e   Horwich, A ^aa   Huddart, R A ^aa   Kliesch, S ^ab   Kollmannsberger, C ^ac   Krege, S ^ad   Laguna, M P ^ae   Looijenga, L H J ^af   Lorch, A ^b   Lotz, J P ^ag   Mayer, F ^ah   Necchi, A ^ai   Nicolai, N ^ai   Nuver, J ^c   Oechsle, K ^e   Oldenburg, J ^l   Oosterhuis, J W ^af   Powles, T ^aj   Rajpert De Meyts, E ^m   Rick, O ^ak   Rosti, G ^al   Salvioni, R ^ai   Schrader, M ^am   Schweyer, S ^an   Sedlmayer, F ^ao   Sohaib, A ^aa   Souchon, R ^ah   Tandstad, T ^ap   Winter, C ^b   Wittekind, C ^aq   more..

^a VIVANTES KLINIKUM AM URBAN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e BMT and Pulmonology University Hospital   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Department of Internal Medicine ^*  (Switzerland)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j St Vincentius Hospital   (Germany)

^k KAROLINSKA INSTITUTE   (Sweden)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m Rigshospitalet   (Denmark)

ⁿ DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^o LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^p VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^q ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^r ALBERTINEN KRANKENHAUS   (Germany)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t INSTITUT GUSTAVE ROUSSY   (France)

^u CENTRE LÉON BÉRARD   (France)

^v BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^w CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^x UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^y UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^z Harlaching Hospital   (Germany)

^aa ROYAL MARSDEN HOSPITAL   (United Kingdom)

^ab INST OF REPRO MED OF THE UNIV   (Germany)

^ac UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ad Maria Hilf Hospital Krefeld   (Germany)

^ae UNIVERSITY OF AMSTERDAM   (Netherlands)

^af ERASMUS MEDICAL CENTER   (Netherlands)

^ag HÔPITAL TENON   (France)

^ah UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^ai NATIONAL CANCER INSTITUTE   (Italy)

^aj ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^ak Hospital Reinhardshöhe   (Germany)

^al OSPEDALE CA FONCELLO   (Italy)

^am UNIVERSITY HOSPITAL ULM   (Germany)

^an Gemeinschaftspraxis Pathologie   (Germany)

^ao PARACELSUS MEDICAL UNIVERSITY   (Austria)

^ap TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^aq UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

Consensus conference; Diagnosis; Germ cell cancer; Late toxic effects; Long term follow up; Treatment

Indexed keywords

ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL; TESTOSTERONE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; GERMANY; HISTOPATHOLOGY; HUMAN; HYPOGONADISM; LUNG TOXICITY; LYMPH NODE DISSECTION; MEDICAL EDUCATION; MEDICAL EXPERT; MEDICAL SPECIALIST; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; REPRODUCTIVE HEALTH; REVIEW; SEMINOMA; TREATMENT RESPONSE;

EID: 84875591927     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds579     Document Type: Review

References (100)

1. Sonne SB, Kristensen DM, Novotny GW et al. Testicular dysgenesis syndrome and the origin of carcinoma in situ testis. Int J Androl 2008; 31: 275-287.
2. Kanetsky PA, Mitra N, Vardhanabhuti S et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009; 41: 811-815.
3. Turnbull C, Rapley EA, Seal S et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 2010; 42: 604-607.
4. Schmoll H-J, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
5. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496.
6. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
7. Van Casteren NJ, de Jong J, Stoop H et al. Evaluation of testicular biopsies for carcinoma in situ: immunohistochemistry is mandatory. Int J Androl 2009; 32: 666-674.
8. Gillis AJ, Stoop H, Biermann K et al. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. Int J Androl. 2011; 34: e160-e174.
9. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972.
10. Nicolai N, Colecchia M, Biasoni D et al. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection. J Urol 2011; 186: 1298-1302.
11. Dieckmann KP, Kulejewski M, Heinemann V et al. (2011) Testicular biopsy for early cancer detection - objectives, technique and controversies. Int J Androl 2011; 34: e7-e13. DOI:10.1111/j.1365-2605.2011.01152.x
12. Hansen J, Jurik AG. Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. Acta Radiol 2009; 50: 1064-1070.
13. Huddart RA, O'Doherty MJ, Padhani A et al. 18 fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22-the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25: 3090-3095.
14. De Wit M, Brenner W, Hartmann M et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008; 19: 1619-1623.
15. Gilligan T, Seidenfeld J, Basch EM. American Society of Clinical Oncology Clinical practice Guidelines on the Uses of tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28: 3388-3404.
16. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
17. Chung PW, Daugaard G, Tydlesley S et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 2010; 28: 15s (abstr 4535).
18. Tandstad T, Smaaland R, Solberg A et al. Management of seminomatous testicular cancer: a binational prospective population-bases study from the Swedish Norwegian testicular cancer study group. J Clin Oncol 2011; 29: 719-725.
19. Aparicio J, Maroto P, del Muro XG et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish germ cell cancer group study. J Clin Oncol 2011; 29: 4677-4681.
20. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19: 443-447.
21. Cummins S, Yau T, Huddart R et al. Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 2010; 57: 673-678.
22. Chung P, Warde P, Stage I. Seminoma: adjuvant treatment is effective but is it necessary? J Natl Cancer Inst 2011; 103: 195-196.
23. Mead GM, Fossa SD, Oliver RTD et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011; 103: 241-249.
24. Oliver TD, Mead GM, Gordon JS et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). J Clin Oncol 2011; 29: 957-962.
25. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
26. Kollmannsberger C, Moore C, Chi KN et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010; 21: 1296-1301.
27. Nicolai N, Miceli R, Necchi A et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol 2010; 58: 912-918.
28. Tandstad T, Cohn-Cedermark G, Dahl O et al. Long-term follow-up after riskadapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 2010; 21: 1858-1863.
29. Sturgeon JF, Moore MJ, Kakiashvili DM et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol 2011; 59: 556-562.
30. Moynihan C, Norman AR, Barbachano Y et al. Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J Clin Oncol 2009; 27: 2144-2150.
31. Yu HY, Madison RA, Setodji CM et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009; 27: 4327-4332.
32. Garcia-del-Muro X, Maroto P, Guma J et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish germ cell cancer group study. J Clin Oncol 2008; 26: 5416-5421.
33. Culine S, Kerbat P, Kramar A et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18: 917-924.
34. Grimison PS, Martin R, Stockler MR et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 2010; 102: 1253-1262.
35. De Wit R, Skoneczna I, Daugaard G et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 2012; 30: 792-799.
36. Daugaard G, Skoneczna I, Aass N et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germcell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22: 1054-1061.
37. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256.
38. Olofsson SE, Tandstad T, Jerkeman M et al. Population based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular Cancer Group. J Clin Oncol 2011; 29: 2032-2039.
39. Bachner M, Loriot Y, Gross-Goupil M et al. 2-18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23: 59-64.
40. Carver BS, Shayegan B, Eggener S et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2007; 25: 4365-4369.
41. Beck SD, Foster RS, Bihrle R et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 2007; 110: 1235-1240.
42. Heidenreich A, Pfister D, Witthuhn R et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2009; 55: 217-226.
43. Carver BS, Cronin AM, Eggener S et al. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology 2010; 75: 1431-1435.
44. Besse B, Grunenwald D, Fléchon A et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg 2009; 137: 448-452.
45. Ehrlich Y, Brames MJ, Beck SD et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28: 531-536.
46. Kollmannsberger C, Daneshmand S, So A et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010; 28: 537-542.
47. Winter C, Pfister D, Busch J et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 2012; 61: 403-409.
48. Pfister D, Busch J, Winter C et al. Pathohistological findings in patients with nonseminomatous germ cell tumours who undergo postchemotherapy retroperitoneal lymph node dissection for small residual lesions. J Urol 2011; 185: e334 (abstract 830).
49. Fizazi K, Oldenburg J, Dunant A et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008; 19: 259-264.
50. Capitanio U, Jeldres C, Perrotte P et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology 2009; 74: 373-377.
51. Flechon A, Tavernier E, Boyle H et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int 2010; 106: 779-785.
52. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-348.
53. Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85-90.
54. The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906-4911.
55. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus highdose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-2184.
56. Lorch A, Kleinhans A, Kramar A et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: longterm results of a prospective randomized trial. J Clin Oncol 2012; 30: 800-805.
57. Simonelli M, Rosti G, Banna GL et al. Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol 2012; 23: 815-822.
58. Lorch A, Neubauer A, Hackenthal M et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germcell tumors. Ann Oncol 2010; 21: 820-825.
59. Oechsle K, Kollmannsberger C, Honecker F et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 2011; 60: 850-855.
60. Nicolai N, Necchi A, Gianni L et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int 2009; 104: 340-346.
61. Eggener SE, Carver BS, Loeb S et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 2007; 109: 528-535.
62. Sharp DS, Carver BS, Eggener SE et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008; 26: 5524-5529.
63. Necchi A, Colecchia M, Nicolai N et al. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU Int. 2011; 107: 1088-1094.
64. Lorch A, Rick O, Wündisch T et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol 2010; 184: 168-173.
65. Powles T, Bower M, Daugaard G et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003; 21: 1922-1927.
66. Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
67. Massard C, Plantade A, Gross-Goupil M et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 2010; 21: 1585-1588.
68. Collette L, Sylvester RJ, Stenning SP et al. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. European organization for research and treatment of cancer genito-urinary tract cancer collaborative group and the medical research council testicular cancer working party. J Natl Cancer Inst 1999; 91: 839-846.
69. Aschim EL, Haugen TB, Tretli S et al. Subfertility among parents of men diagnosed with testicular cancer. Int J Androl 2008; 31: 588-594.
70. Brydoy M, Fossa SD, Klepp O et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 2010; 58: 134-140.
71. Kim C, McGlynn KA, McCorkle R et al. Fertility among testicular cancer survivors: a case-control study in the US. J Cancer Surviv 2010; 4: 266-273.
72. Stensheim H, Cvancarova M, Moller B et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 2011; 129: 1225-1236.
73. Stahl O, Boyd HA, Giwercman A et al. Risk of birth anomalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst 2011; 103: 398-406.
74. Kliesch S, Kamischke A, Cooper TG et al. Cryopreservation of human spermatozoa. In Nieschlag E, Behre HM, Nieschlag S (eds), Andrology-Male Reproductive Health and Dysfunction, 3rd edition. Springer 2010; 505-520.
75. Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2008; 55: 121-130.
76. Abouassaly R, Fossa SD, Giwercman A et al. Sequelae of treatment in longterm survivors of testis cancer. Eur Urol 2011; 60: 516-526.
77. Altena R, Hummel YM, Nuver J et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011; 22: 2286-2293.
78. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-399.
79. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-4657.
80. De Haas EC, Altena R, Boezen HM et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013; 24: 749-755.
81. Brydoy M, Oldenburg J, Klepp O et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101: 1682-1695.
82. Glendenning JL, Barbachano Y, Norman AR et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116: 2322-2331.
83. Travis LB, Beard C, Allan JM et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102: 1114-1130.
84. Rossen PB, Pedersen AF, Zachariae R et al. Health-related quality of life in longterm survivors of testicular cancer. J Clin Oncol 2009; 27: 5993-5999.
85. Kim C, McGlynn KA, McCorkle R et al. Quality of life among testicular cancer survivors: a case-control study in the United States. Qual Life Res 2011; 20: 1629-1637.
86. Shinn EH, Basen-Engquist K, Thornton B et al. Health behaviors and depressive symptoms in testicular cancer survivors. Urology 2007; 69: 748-753.
87. Grov EK, Fossa SD, Bremnes RM et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol 2009; 48: 842-849.
88. Orre IJ, Fossa SD, Murison R et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 2008; 64: 363-371.
89. Skaali T, Fossa SD, Andersson S et al. Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 2011; 70: 403-410.
90. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284.
91. Mettler FA, Bhargavan M, Faulkner K et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources-1950-2007. Radiology 2009; 253: 520-531.
92. Fazel R, Krumholz HM, Wang Y et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361: 849-857.
93. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181: 627-633.
94. Van As NJ, Gilbert DC, Money-Kyrle J et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008; 98: 1894-1902.
95. Cathomas R, Helbling D, Stenner F et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkly 2010; 140: 356-369.
96. Albers P, Albrecht W, Algaba F et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304-319.
97. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440.
98. Nichols C, Catalano PJ, Crawford ED et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998; 16: 1287-1293.
99. Loehrer PJ, Lauer R, Roth BJ et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540-546.
100. Kondagunta GV, Bacik J, Donnadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6545-6555.